Search clinical trials for: Mirikizumab Prefilled Syringe

Total 2048 results

Boehringer Ingelheim

Completed

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

Healthy

Belgium
Imperial College London
British Heart Foundation

Completed

Investigation of Leukocyte Trafficking Into Skin Blisters During Cardiopulmonary Bypass

Angina Pectoris | Ischemic Heart Disease

United Kingdom
Pfizer

Completed

Drug Interaction Study Between Bosutinib And Dabigatran

Healthy

United States
AstraZeneca

Terminated

Long Term Open Follow-up With H376/95 vs. Warfarin

Stroke Prevention in Patients With Atrial Fibrillation

Sweden, Norway, Poland, United Kingdom, Finland, Denmark, United States, Czech Republic, Belgium
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients (Thrombosis)

Cancer | Catheter Complications | Thrombosis, Venous

China
Daiichi Sankyo
Daiichi Sankyo Korea Co., Ltd.

Recruiting

A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation (SILVERCARE_AF)

Atrial Fibrillation

Korea, Republic of
University Hospital, Tours

Not yet recruiting

Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients (CARD-AXA)

Chronic Hemodialysis Patients
Mayo Clinic
Ottawa Heart Institute Research Corporation

Recruiting

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion (CAPITAL-RAPTOR)

Radial Artery Occlusion

United States
Sichuan Provincial People's Hospital

Recruiting

Treatment of ARDS With Sivelestat Sodium (TOAWSS)

Acute Respiratory Distress Syndrome

China
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Apixaban

Obesity, Morbid

Norway
Bayer

Completed

An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World Setting

Atrial Fibrillation | Prevention of Thromboembolic Events

United States
Daiichi Sankyo, Inc.
Daiichi Sankyo (China) Holdings Co., Ltd.

Active, not recruiting

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China (ETNA-AF-CHINA)

Non-valvular Atrial Fibrillation

China
The Medicines Company

Withdrawn

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

Heparin-Induced Thrombocytopenia | Heparin-induced Thrombocytopenia and Thrombosis Syndrome

United States
LiuZhou People's Hospital

Unknown

Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports

Cancer | Rivaroxaban | Thromboprophylaxis
Prof. Stavros Konstantinides, MD
European Georges Pompidou Hospital

Terminated

Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism. (PEITHO-2)

Pulmonary Embolism

Germany
The Medicines Company

Completed

Bivalirudin as a Procedural Anticoagulant in Pediatrics

Cardiology
The Medicines Company

Completed

Study Of Angiomax In Infants Under Six Months With Thrombosis

Thrombosis

United States
RenJi Hospital

Not yet recruiting

Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves

Anticoagulation
The Affiliated Hospital Of Guizhou Medical University

Not yet recruiting

Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran

Combined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters
Peking Union Medical College Hospital
Xiangya Hospital of Central South University; Ruijin Hospital; China-Japan Friendship...

Recruiting

The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics

Pulmonary Embolism

China
University of Vermont Medical Center
Dartmouth-Hitchcock Medical Center; MaineHealth

Not yet recruiting

Venous Thromboembolism Prevention in Outpatients With Glioma (VTE-POG)

Glioblastoma | Astrocytoma | Venous Thromboembolism
Chinese University of Hong Kong
Prince of Wales Hospital, Shatin, Hong Kong

Recruiting

Pharmacokinetics of Apixaban in Peritoneal Dialysis

Atrial Fibrillation

Hong Kong
Seoul National University Hospital

Not yet recruiting

Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation

Fontan Operation | Protein-Losing Enteropathy | Camostat Mesylate
China National Center for Cardiovascular Diseases

Recruiting

An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE) (R-DISSOLVE)

Ventricular Mural Thrombosis

China
General Hospital of Shenyang Military Region

Recruiting

Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation (ERSAF)

Cerebral Infarction | TIA

China
Seoul National University Hospital

Active, not recruiting

Efficacy and Safety of Apixaban in Korean Frail Atrial Fibrillation Patient

Atrial Fibrillation

Korea, Republic of
Loxo Oncology, Inc.
Eli Lilly and Company

Completed

A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants

Healthy

United States
Stanford University

Completed

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol

Covid19

United States
Stanford University

Terminated

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol (COPPS)

Covid19

United States
Assistance Publique - Hôpitaux de Paris

Terminated

CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients (CAMOVID)

Covid19

France
Boehringer Ingelheim

Completed

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Arthroplasty, Replacement | Prevention of Venous Thromboembolism | Moderate Renal Impairment (CrCl 30-50 mL/Min)

Austria, Canada, Czechia, Finland, Netherlands, Sweden
University Hospital Inselspital, Berne

Terminated

Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. (CATHAR)

Aortic Valve Disease | Anticoagulants | Heart Valve Prosthesis Implantation

Switzerland
Bristol-Myers Squibb

Completed

Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France

Anticoagulation

France
Janssen Scientific Affairs, LLC
Bayer

Completed

Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants

Pharmacokinetics | Healthy Participants | Bioavailability

United States
Yonsei University

Completed

Effect of Ulinastatin on Postoperative Renal Function in Patients Undergoing Robot-assisted Laparoscopic Partial Nephrectomy

Renal Mass

Korea, Republic of
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Hepatic Insufficiency
Pfizer

Completed

Food Effect Study For Apixaban Commercial Image Tablets

Healthy

Singapore
Texas Biotechnology Corporation

Completed

Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis

Kidney Failure, Chronic | Renal Disease, End-Stage

United States
Maastricht University

Not yet recruiting

In Vivo Effects of Amylase Trypsin Inhibitors (ATI)

Irritable Bowel Syndrome | Non-Coeliac Wheat Sensitivity (NCWS)
Ono Pharmaceutical Co. Ltd

Completed

A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)

SARS-CoV-2 Infection (COVID-19)

Japan
Portola Pharmaceuticals

Completed

A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers

Healthy Subjects
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe (ETNA-VTE)

Venous Thromboembolism

Germany
Bristol-Myers Squibb

Available

Expanded Access for Apixaban

United States
Stanford University

Withdrawn

Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients

COVID-19

United States
Daiichi Sankyo, Inc.

Completed

Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)

Atrial Fibrillation

Korea, Republic of, Taiwan
Jong Sung Kim
Dong-A University Hospital; Soon Chun Hyang University; Kyung Hee University...

Completed

Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation

Acute Ischemic Stroke

Korea, Republic of
Hong Kong WD Pharmaceutical Co., Limited

Unknown

A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition

Anticoagulant
Nirmish Shah
Bristol-Myers Squibb

Terminated

Apixaban in Patients With Sickle Cell Disease

Sickle Cell Disease | Vaso-occlusive Crisis | Reduction in Hospitalizations

United States
Gregory Piazza
Bristol-Myers Squibb

Completed

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

Multiple Myeloma | Venous Thromboembolism

United States
Ostfold Hospital Trust

Completed

Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study (Ri-Schedule)

Deep Venous Thrombosis

Norway

Search clinical trials for: Mirikizumab Prefilled Syringe

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations